|
1
|
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer. Nat Rev Clin Oncol 2024; 21:402. [PMID: 38565936 DOI: 10.1038/s41571-024-00889-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
|
|
2
|
Afami-cel provides a novel treatment option for rare sarcoma subtypes. Nat Rev Clin Oncol 2024; 21:401. [PMID: 38637649 DOI: 10.1038/s41571-024-00894-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/20/2024]
|
|
3
|
A new standard of care for advanced-stage urothelial carcinoma. Nat Rev Clin Oncol 2024; 21:336. [PMID: 38509334 DOI: 10.1038/s41571-024-00884-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2024]
|
|
4
|
Pegargiminase improves outcomes in nonepithelioid MPM. Nat Rev Clin Oncol 2024; 21:336. [PMID: 38438632 DOI: 10.1038/s41571-024-00878-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2024]
|
|
5
|
Laparoscopic hemihepatectomy is safe and effective. Nat Rev Clin Oncol 2024:10.1038/s41571-024-00900-3. [PMID: 38684929 DOI: 10.1038/s41571-024-00900-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2024]
|
|
6
|
Adjuvant pembrolizumab improves overall survival in patients with RCC. Nat Rev Clin Oncol 2024:10.1038/s41571-024-00901-2. [PMID: 38684928 DOI: 10.1038/s41571-024-00901-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2024]
|
|
7
|
KN046 shows tolerability and activity in TNBC. Nat Rev Clin Oncol 2024; 21:251. [PMID: 38365954 DOI: 10.1038/s41571-024-00872-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2024]
|
|
8
|
Adjuvant sintilimab effective in high-risk HCC. Nat Rev Clin Oncol 2024; 21:168. [PMID: 38316989 DOI: 10.1038/s41571-024-00865-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2024]
|
|
9
|
Repotrectinib effective in ROS1-fusion-positive NSCLC. Nat Rev Clin Oncol 2024; 21:167. [PMID: 38278875 DOI: 10.1038/s41571-024-00864-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2024]
|
|
10
|
Tovorafenib effective against low-grade gliomas harbouring BRAF fusions. Nat Rev Clin Oncol 2024; 21:83. [PMID: 38082106 DOI: 10.1038/s41571-023-00845-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2024]
|
|
11
|
Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer. Nat Rev Clin Oncol 2024; 21:83. [PMID: 38114788 DOI: 10.1038/s41571-023-00851-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2023]
|
|
12
|
From ESMO 2023: advances in lung cancer. Nat Rev Clin Oncol 2024; 21:4. [PMID: 37923903 DOI: 10.1038/s41571-023-00838-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2023]
|
|
13
|
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC. Nat Rev Clin Oncol 2023; 20:817. [PMID: 37749383 DOI: 10.1038/s41571-023-00822-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/27/2023]
|
|
14
|
Sacituzumab govitecan improves OS in heavily pretreated patients. Nat Rev Clin Oncol 2023; 20:734. [PMID: 37684406 DOI: 10.1038/s41571-023-00818-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/10/2023]
|
|
15
|
BRAF plus MEK inhibition effective in papillary craniopharyngioma. Nat Rev Clin Oncol 2023; 20:661. [PMID: 37491596 DOI: 10.1038/s41571-023-00807-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2023]
|
|
16
|
Capivasertib delays disease progression. Nat Rev Clin Oncol 2023; 20:579. [PMID: 37311901 DOI: 10.1038/s41571-023-00790-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
|
|
17
|
Adjuvant osimertinib improves overall survival. Nat Rev Clin Oncol 2023; 20:504. [PMID: 37311902 DOI: 10.1038/s41571-023-00791-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
|
|
18
|
SUNLIGHT illuminates the activity of bevacizumab. Nat Rev Clin Oncol 2023:10.1038/s41571-023-00784-9. [PMID: 37198414 DOI: 10.1038/s41571-023-00784-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
|
|
19
|
T-DXd is effective after T-DM1. Nat Rev Clin Oncol 2023:10.1038/s41571-023-00779-6. [PMID: 37173585 DOI: 10.1038/s41571-023-00779-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
|
|
20
|
|
|
21
|
From AACR 2023. Nat Rev Clin Oncol 2023; 20:354. [PMID: 37130914 DOI: 10.1038/s41571-023-00771-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
|
|
22
|
New combination therapy for advanced-stage RCC. Nat Rev Clin Oncol 2023; 20:353. [PMID: 37041275 DOI: 10.1038/s41571-023-00765-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/13/2023]
|
|
23
|
Radiotherapy can be omitted for older patients with low-risk disease. Nat Rev Clin Oncol 2023; 20:210. [PMID: 36854808 DOI: 10.1038/s41571-023-00750-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
|
|
24
|
Early data indicate safety of allogeneic CAR T cells. Nat Rev Clin Oncol 2023; 20:209. [PMID: 36750648 DOI: 10.1038/s41571-023-00739-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
|
25
|
Nirogacestat effective in desmoid tumours. Nat Rev Clin Oncol 2023; 20:284. [PMID: 36997640 DOI: 10.1038/s41571-023-00758-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/01/2023]
|
|
26
|
Neoadjuvant pembrolizumab improves outcomes. Nat Rev Clin Oncol 2023; 20:284. [PMID: 36899061 DOI: 10.1038/s41571-023-00752-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/12/2023]
|
|
27
|
Brentuximab vedotin improves outcomes. Nat Rev Clin Oncol 2023; 20:2. [PMID: 36418475 DOI: 10.1038/s41571-022-00715-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
|
28
|
Laparoscopic TME is non-inferior. Nat Rev Clin Oncol 2022; 19:748. [PMID: 36202995 DOI: 10.1038/s41571-022-00695-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
|
29
|
Novel combination delivers prolonged OS. Nat Rev Clin Oncol 2022; 19:676. [PMID: 36180787 DOI: 10.1038/s41571-022-00692-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
30
|
Liso-cel effective in R/R LBCL. Nat Rev Clin Oncol 2022; 19:567. [PMID: 35918608 DOI: 10.1038/s41571-022-00673-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
31
|
T-DXd active in HER2-low disease. Nat Rev Clin Oncol 2022; 19:493. [PMID: 35778612 DOI: 10.1038/s41571-022-00663-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
32
|
Tiragolumab active in PD-L1 + NSCLC. Nat Rev Clin Oncol 2022; 19:428. [PMID: 35606416 DOI: 10.1038/s41571-022-00650-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
33
|
From AACR 2022. Nat Rev Clin Oncol 2022; 19:359. [PMID: 35505232 DOI: 10.1038/s41571-022-00642-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
34
|
Pembrolizumab improves EFS in TNBC. Nat Rev Clin Oncol 2022; 19:220. [PMID: 35217781 DOI: 10.1038/s41571-022-00614-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
35
|
|
|
36
|
Axicabtagene effective in indolent NHL. Nat Rev Clin Oncol 2021; 19:150. [PMID: 34937949 DOI: 10.1038/s41571-021-00596-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
37
|
|
|
38
|
MSI-H/dMMR mCRC: ICIs in the first line? Nat Rev Clin Oncol 2021; 18:748. [PMID: 34697487 DOI: 10.1038/s41571-021-00576-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
39
|
T-DXd effective in HER2-mutant NSCLC. Nat Rev Clin Oncol 2021; 18:748. [PMID: 34611335 DOI: 10.1038/s41571-021-00569-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
40
|
TILs show early efficacy. Nat Rev Clin Oncol 2021; 18:603. [PMID: 34453131 DOI: 10.1038/s41571-021-00555-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
41
|
Adjuvant pembrolizumab shows promise. Nat Rev Clin Oncol 2021; 18:604. [PMID: 34453132 DOI: 10.1038/s41571-021-00554-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
42
|
|
|
43
|
|
|
44
|
|
|
45
|
Enfortumab vedotin is safe and effective. Nat Rev Clin Oncol 2021; 18:400. [PMID: 34031573 DOI: 10.1038/s41571-021-00525-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
46
|
|
|
47
|
|
|
48
|
|
|
49
|
Trastuzumab deruxtecan improves survival. Nat Rev Clin Oncol 2020; 17:521. [DOI: 10.1038/s41571-020-0406-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
|
50
|
From AACR 2020 (part 1). Nat Rev Clin Oncol 2020; 17:390. [PMID: 32404992 PMCID: PMC7220572 DOI: 10.1038/s41571-020-0386-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|